Web Exclusives

The FDA recently approved Mekinist (trametinib) in combination with Tafinlar (dabrafenib) to treat patients with advanced melanoma that is unresectable (cannot be removed by surgery) or metastatic (late-stage).
Onco360 Expected to Rapidly Grow Revenues Over the Next Several Years
MedImpact Healthcare Systems, Inc. and Onco360 today announced a joint collaboration focused on offering MedImpact clients a unique and effective solution for bending the cost curve and delivering quality and value-based Oncology pharmaceutical care.
Novel therapies for patients with multiple myeloma (MM) continue to show improved outcomes for a population that as little as 8 years ago had few options.
Most of the illnesses that are encountered in medicine are incurable. Diabetes and heart disease are 2 of the common, chronic, and incurable health conditions that require diligent monitoring.
The past decade has given us several breakthrough treatment options for a complex and serious malignancy, multiple myeloma (MM).
Multiple myeloma (MM) accounts for 10% to 15% of all hematologic malignancies, and is the cause of 20% of the deaths that result from blood and bone cancers.

Carfilzomib (Kyprolis, Onyx Pharmaceuticals, Inc, South San Francisco, CA) is a selective proteasome inhibitor that irreversibly binds to active sites within the proteolytic core of the 26S proteasome, resulting in inhibition of proteasome activity. Preclinical studies have shown carfilzomib inhibits tumor growth and promotes tumor cell death, with sustained proteasome inhibition for more than 48 hours when using a consecutive-day dosing regimen.1-4

ES has received 5 prior lines of therapy, with progression of disease documented on her most recent therapy with a rise in SPEP from 1.3 to 2.2 g/dL and in UPEP from 556 to 1342 mg/24 hours. The current clinical considerations include anemia, renal insufficiency, and PN grade 1 with pain.

Carfilzomib (Kyprolis, Onyx Pharmaceuticals, South San Francisco, CA) is a proteasome inhibitor that recently received accelerated FDA approval as single-agent treatment for relapsed or refractory multiple myeloma (RRMM),1 as well as designation as a “Preferred Regimen” for salvage therapy according to the National Comprehensive Cancer Network (NCCN) guidelines.2 Carfilzomib differs structurally and mechanistically from bortezomib; it functions by irreversibly inhibiting chymotrypsin-like activity of the constitutive proteasome and the immunoproteasome and offers a novel treatment option for patients with advanced MM.3

Page 20 of 31
Results 191 - 200 of 302